Meditip, a leading Korean CRO specializing in authorization. merged with DreamCIS in 2022, becoming a subsidiary of TigerMed. Our integrated network, including LCS for non-clinical, DreamCIS for clinical trials, Meditip for authorization, and TigerMed for global clinical approval, enables us to offer comprehensive consulting services from R&D to commercialization.
Meditip plays a crucial role throughout the process, helping to save costs and time from a regulatory perspective....
